Issues of Large-Scale Plasmid DNA Manufacturing

Biotechnology: Second, Completely Revised Edition

Volumn 5-12, Issue , 2008, Pages 443-469

  Schleef, Martin ^a  

^a QIAGEN GMBH   (Germany)

Author keywords

Eukaryotic cells; Immunogenic; Specifications; Stability; Therapeutic

Indexed keywords

EID: 84978760315     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527620999.ch20d     Document Type: Chapter

References (83)

1. Anonymous (1998), Europäisches Arzneibuch, Nachtrag 1998. Stuttgart: Deutscher Apotheker Verlag; Eschborn: Govi-Verlag-Pharmazeu-tischer Verlag GmbH.
2. AUTERHOFF, G. (1997), EC Guide to Good Manufacturing Practice for Medical Products, 2nd Edn. Aulendorf: ECV.
3. BADER, F. G., BLUM, A., GARFINKE, B. D., MAC-FARLANE, D., MASSA, T., COPMANN, T. L. (1992), Multiuse manufacturing facilities for bio-logicals, Biopharm 5, 32-40.
4. BARRY, A. R., CHOJNACKI, R. (1995), Biotechnology product validation, Part 8: Chromatography media and column qualification, Pharm. Tech-nol. Eur. 6, 32-38.
5. BEHR, J. P. (1994), Gene transfer with synthetic cationic amphiphiles: Prospects for gene therapy, Bioconj. Chem. 5, 382-389.
6. BIRNBOIM, H. C, DOLY, J. (1979), A rapid alkaline extraction procedure for screening recombinant plasmid DNA, Nucleic Acids Res. 7, 1513-1523.
7. CAPLEN, N. J., GAO, X., HAYES, P., ELASWARA-PU, R., FISHER, G. et al. (1994), Gene therapy for cystic fibrosis in humans by liposome-me-diated DNA transfer: U.K. regulatory process and production of resources, Gene Ther. 1, 139-147.
8. CBER (1996), Points to Consider on Plasmid DNA Vaccines for Preventive Infectious Disease Indications, Rockville, MD: Center for Biologies Evaluation and Research (HFM-630), FDA.
9. CBER (1998), Guidance for Industry: Guidance for Human Somatic Cell Therapy and Gene Therapy, Rockville, MD: Center for Biologies Evaluation and Research, FDA.
10. CDER (1987), Guidelines on General Principles of Process Validation, Rockville, MD: Center for Drug Evaluation and Research, FDA, Division of Manufacturing and Product Quality (HFD-320), .
11. CFR-21 (1991), Current Good Manufacturing Practice in Manufacturing, Processing, Packaging, or Holding of Drugs; General, Code of Federal Regulations, Title 21, Part 210.
12. CHANDRA, G., PATEL, P., KOST, T. A., GRAY, J. G. (1992), Large-scale purification of plasmid DNA by fast protein liquid chromatography using a Hi-load Q sepharose column, Anal. Bio-chem. 203, 169-172.
13. CHAPMAN, K. G. (1991), A history of validation in the United States: Part I, Pharm. Technol. 15, 82-96.
14. CHEN, W., GRAHAM, C, CICCARELLI, R. B. (1997), Automated fed-batch fermentation with feed-back controls based on dissolved oxygen (DO) and pH for production of DNA vaccines, J. Ind. Microbiol. Biotechnol. 18, 43-48.
15. CICHUTEK, K., KRAMER, I. (in press), Gene therapy in Germany and in Europe: Regulatory issues, Qual. Assur. J.
16. COLPAN, M., SCHORR, I., MORITZ, P. (1995), Process for producing endotoxin-free or endotoxin-poor nucleic acids and/or oligonucleotides for gene therapy, WO 95/21177.
17. COTTEN, M., BAKER, A., SALTIK, M., WAGNER, E., BUSCHLE, M. (1994), Lipopolysaccaride is a frequent contamination of plasmid DNA preparations and can be toxic to primary cells in the presence of adenovirus, Gene Ther. 1, 239-246.
18. DASARTHY, Y., RAMBERG, M., ANDERSSON, M. (1996), A systematic approach to screening ion-exchange chromatography media for process development, Biopharm 9, 42-45.
19. DAVIS, B. D., DULBECCO, R., EISEN, H. H., GINSBERG, H. S. (1980), Microbiology, 3rd Edn. Philadelphia, PA: Harper and Row.
20. DESAIN, C (1991), Master production batch records, Biopharm 4, 20-24.
21. DONNELLY, I. J., ULMER, I. B., Liu, M. A. (1997), DNA Vaccines Life Sci. 60, 163-172.
22. European Council Directive (1990), Council Directive of April 23, 1990 on the contained use of genetically modified microorganisms (90/219/ EEC) (Amtsblatt der EG, Nr. L117 vom 8. Mai, 1990, page Iff., and the adaption thereof (94/51/ EG) from November 07, 1994).
23. FELGNER, P. L., GADEK, T. R., HOLM, M., ROMAN, R., CAHN, H. W. et al. (1987), Lipofectin: A highly efficient, lipid-mediated DNA transfec-tion procedure, Proc. Natl. Acad. Sci. USA 84, 7413-7417.
24. GRAHAM, F. L., VAN DER EB, A. L. (1973), A new technique for the assay of infectivity of human adenovirus 5 DNA, Virology 52, 456-467.
25. GREEN, A. P., PRIOR, G. M., HELVESTON, N. M., TAITTINGER, B. E., LIN, X., THOMPSON, J. A. (1997), Preparative purification of supercoiled plasmid DNA for therapeutic applications, Biopharm 10, 52-62.
26. GREGORIADIS, G. (1998), Genetic vaccines: Strategies for optimization, Pharm. Res. 15, 661-670.
27. GÜNZBURG, W. H., SALMONS, B. (Eds.) (1997), Gentransfer in Säugetierzellen. Heidelberg: Spektrum Akademischer Verlag.
28. HELINSKI, D. (1979), Bacterial plasmids: Autonomous replication and vehicles for gene cloning, CRC Crit. Rev. Biochem. 7, 83-101.
29. HORN, N, BUDAHAZI, G., MARQUET, M. (1998), U.S. Patent 5 707 812.
30. ISH-HOROWICS, D., BURKE, I. F. (1981), Rapid and efficient cosmid cloning, Nucleic Acids Res. 9, 2989-2998.
31. ISNER, I. M., WALSH, I., SYMES, A., PIECZEK, A., TAKESHITA, S. et al. (1995), Arterial gene therapy for therapeutic angiogenesis in patients with peripheral artery disease, Circulation 91, 2687-2692.
32. KITTLE, I. D., PIMENTEL, B. I. (1997), Testing the genetic stability of recombinant DNA cell banks, Biopharm 10, 30-35.
33. KORZ, D. I., RINAS, U., HELLMUTH, K, SANDERS, E. A., DECKWER, W.-D. (1995), Simple fed-batch technique for high cell density cultivation of Escherichia coli, J. Biotechnol. 39, 59-65.
34. KRIEG, A. M. (1996), Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA, Trends Microbiol. 4,11-11.
35. KRIEG, A. M., Yi, A.-K, MATSON, S., WALD-SCHMIDT, T. J., BISHOP, G. A. et al. (1995), CpG motifs in bacterial DNA trigger direct B-cell activation, Nature 374, 546-549.
36. KUHNE, W. (1997), Process for preparing purified nucleic acid and the use thereof, WO 97/29113.
37. LAHIJANI, R., HULLEY, G., SORIANO, G., HORM, N. A., MARQUET, M. (1996), High-yield production of pBR322-derived plasmids intended for human gene therapy by employing a temperature-controllable point mutation, Hum. Gene Ther. 7, 1971-1980.
38. LE BORGNE, S., MANCINI, M., LE GRAND, R., SCHLEEF, M., DORMONT, D. et al. (1998), In vivo induction of specific cytotoxic T lymphocytes in mice and rhesus macaques immunized with DNA vector encoding an HIV epitope fused with hepatitis B surface antigen, Virology 240, 304-315.
39. LEE, J. Y. (1989), Environmental requirements for clean rooms, Biopharm 2,42-t5.
40. LEE, A. L., SAGAR, S. (1996), A method for large-scale plasmid purification, WO96/36706.
41. MAJOR, M. E., VITVITSKI, L., MINK, M. A., SCHLEEF, M., WHALEN, R. G. et al. (1995), DNA-based immunization with chimeric vectors for the induction of immune responses against the hepatitis C virus nucleocapsid, J. Virol. 69, 5798-5805.
42. MARQUET, M., HORN, N., MEEK, J., BUDAHAZI, G. (1995a), Production of pharmaceutical-grade plasmid DNA, WO 95/21250.
43. MARQUET, M., HORN, N, MEEK, J. (1995b), Process development for the manufacture of plasmid DNA vectors for use in gene therapy, Biopharm 8, 26-37.
44. MEAGER, A., ROBERTSON, I. S. (1998), Regulatory and standardization issues for DNA and vectored vaccines, Curr. Res. Mol. Ther. 1, 262-265.
45. MESSING, S. H. (1998), Outsourcing biopharmaceu-tical manufacturing operations, Biopharm 11, 28-30.
46. METZNER, B. (1997), Criteria for the design of cleanrooms in biotechnology, Swiss Pharma 19, 5-8.
47. MICHEL, M.-L., DAVIS, H. L., SCHLEEF, M., MAN-CINI, M., TIOLLAIS, P., WHALEN, R. G. (1995), DNA-mediated immunization to the hepatitis B surface antigen in mice: Aspects of the humoral response mimic hepatitis B viral infection in humans, Proc. Natl. Acad. Sci. USA 92, 5307-5311.
48. MORRISON, D. C, RYAN, J. L. (1987), Endotoxins and disease mechanism, Annu. Rev. Med. 38, 417-432.
49. NAGLAK, T. L., KEITH, M. G., OMSTEAD, D. R. (1994), Validation of fermentation processes, Biopharm 7, 28-36.
50. NEIDHARDT, F. C. (Ed.) (1996), Escherichia coli and Salmonella typhimurium, 2nd Edn., Vols. 1 and 2. Washington, D.C.: ASM Press.
51. NEUMANN, E., SCHAEFER-RIDDER, M., WANG, Y., HOFSCHNEIDER, P. H. (1982), Gene transfer into mouse lyoma cells by electroporation in high electric fields, EMBO J. 7, 841-845.
52. ORR, T. (1998), Product recovery and purification, Gen. Eng. News 18,No. 5.
53. PARASRAMPURIA, D. A., HUNT, C. A. (1998), Therapeutic delivery issues in gene therapy, Part 1: Vectors, Biopharm 11, 38-45.
54. ROBERTSON, L. S. (1994), Safety considerations for nucleic acid vaccines, Vaccine 12, 1526-1528.
55. ROSCIOLI, N. A., RENSHAW, C. A., GILBERT, A. A., KERRY, C. F., PROBST, P. G. (1996), Environmental monitoring considerations for biological manufacturing, Biopharm 9, 32-40.
56. SAMBROOK, L., FRITSCH, E. F., MANIATIS, T. (1989), Molecular Cloning, 2nd Edn. Cold Spring Harbor, FL: CSH Laboratory Press.
57. SATO, Y., ROMAN, M., TIGHE, H., LEE, D., CORR, M. et al. (1996), Immunstimulatory DNA sequences necessary for effective intradermal gene immunization, Science 273, 352-354.
58. SAUER, P., MÜLLER, M., KANG, J. (1998), Quantification of DNA, QIAGEN News 2, 23-26.
59. SCHLEEF, M., MORTIZ, P., SCHORR, I. (1996), How to produce nucleic acids for human gene therapy and genetic vaccination under full cGMP pharmaceutical manufacturing conditions, Eur. J. Pharm. Sci. 4,S25.
60. SCHMIDT, T., FRIEHS, K, FLASCHEL, E. (1996), Rapid determination of plasmid copy number, J. Biotechnol. 49, 219-229.
61. SCHORR, J., MORITZ, P., SEDDON, T, SCHLEEF, M. (1995), Plasmid DNA for human gene therapy and DNA vaccines, N. Y. Acad. Sci. 772, 271-273.
62. SCHWAB, H. (1993), Principles of genetic engineering for Escherichia coli, in: Genetic Engineering of Microorganisms (PÜHLER, A., Ed.), pp. 1-54. Weinheim: VCH.
63. SEELY, R. L., WIGHT, H. D., FRY, H. H., RUDGE, S. R., SLAFF, G. F. (1994), Biotechnology product validation, Part 7: Validation of chromatography resin useful life, Pharm. Technol. Eur. 6, 32-38.
64. SMITH, H. A., GOLDENTHAL, K. L., VOGEL, F. R., RABINOVICH, R., AGUADO, T. (1997), Workshop on the control and standardization of nucleic acid vaccines, Vaccine 15, 931-933.
65. STEUR, A., OSTROVE, I. M. (1996), Establishing cell banks under current good manufacturing practices, Biopharm 9, 40-44.
66. SUMMERS, D. K. (1996), The Biology of Plasmids. Oxford: Blackwell Science.
67. TANG, M. X., REDEMANN, C. T., SZOKA, F. C. (1996), In vitro gene delivery by degraded po-lyamidoamine dendrimers, Bioconj. Chem. 7, 703-714.
68. TATUM, E. L. (1966), Molecular biology, nucleic acids, and the future of medicine, Perspect. Biol. Med. 10, 19-32.
69. THATCHER, D. R., HITCHCOCK, A. G., HANAK, L. A., VARLEY, D. L. (1997), Method of plasmid DNA production and purification, WO 97/ 29190.
70. THEODOSSIOU, I., COLLINS, I. J., WARD, J. M., THOMAS, O. R. T., DUNNILL, P. (1997), The processing of a plasmid-based gene from E. coli. Primary recovery by filtration, Bioprocess Eng. 16, 175-183.
71. THEODOSSIOU, I., THOMAS, O. R. T, DUNNILL, P. (in press), Methods of enhancing the recovery of plasmid genes from neutralized cell lysate, Bioprocess Eng.
72. TOLBERT, W. R., MERCHANT, B., TAYLOR, J. A., PERGOLIZZI, R. G. (1996), Designing an initial gene therapy manufacturing facility, Biopharm 9, 32-40.
73. TSE-DINH, Y.-C, Qi, H., MENZEL, R. (1997), DNA supercoiling and bacterial adaption: Thermotol-erance and thermoresistance, Trends Microbiol. 5, 323-326.
74. TJSP23 (1995), The United States Pharmacopoeia, 23. Rockville, MD: United States Pharmacopoeia Convention, Inc.
75. VOGEL, F. R., SARVER, H. (1995), Nucleic acid vaccines, Clin. Microbiol. Rev. 8, 406-410.
76. VUKAJLOVICH, S. W., HOFFMAN, J., MORRISON, D. (1987), Activation of human serum complement by bacterial lipopolysaccarides: Structural requirements for antibody independent activation of the classic and alternative pathways, Mol. Immunol. 24, 319-331.
77. WEBER, M., MOLLER, K., WELZECK, M., SCHORR, J. (1995), Effects of lipopolysaccharide on trans-fection efficiency in eukaryotic cells, Biotech-niques 19, 930-940.
78. WHO (1997), Guidelines for Assuring the Quality of DNA Vaccines, Geneva; WHO Technical Report .
79. WICKS, I. P., HOWELL, M. L., HANCOCK, T., KOH-SAKA, H., OLEE, T, CARSON, D. A. (1995), Bacterial lipopolysaccaride copurifies with plasmid DNA: Implications for animal models and human gene therapy, Hum. Gene Ther. 6, 317-323.
80. WILFINGER, W. W., MACKEY, K., CHOMCZYNSKI, P. (1997), Effect of pH and ionic strength on the spectrophotometric assessment of nucleic acid purification, Biotechniques 22, 474-181.
81. WILLIAMS, S. G., CRANENBURGH, R. M., WEISS, A. M. E., WRIGHTON, C J., SHERRATT, D. J., HANAK, J. A. I. (1998), Repressor titration: A novel system for selection and stable maintenance of recombinant plasmids, Nucleic Acids Res. 26, 2120-2124.
82. WILS, P., ESCRIOU, V., WARNERY, A., LACROIX, F., LAGNEAUX, D. et al. (1997), Efficient purification of plasmid DNA for gene transfer using triple-helix affinity chromatography, Gene Ther. 4, 323-330.
83. WOLFF, J. A., WILLIAMS, P., ACSADI, G., IIAO, S., IANI, A., CHONG, W. (1991), Conditions affecting direct gene transfer into rodent muscle in vivo, Biotechniques 11, 474-185.